CTNNB1突变与基质金属蛋白酶在子宫内膜癌抗血管生成治疗中的作用
本研究通过TCGA RNA表达与CPTAC蛋白表达分析及细胞、异种移植实验,探索CTNNB1突变子宫内膜癌对贝伐珠单抗应答的介导因子。结果显示CTNNB1突变与β-catenin及MMP7蛋白丰度升高相关(P<0.001),而过表达β-catenin不增加VEGF-A但增加MMP7表达与分泌(P<0.03),沉默CTNNB1降低MMP7基因表达(P<0.0001),微血管密度未增加。作者据此提出MMP7可能通过消化VEGFR-1释放VEGF-A的机制假说。
要点
- CTNNB1突变子宫内膜癌中β-catenin与MMP7蛋白丰度升高(P<0.001),VEGF-A蛋白丰度未升高。
- 过表达β-catenin增加MMP7表达与分泌(P<0.03),不增加VEGF-A丰度。
- 沉默CTNNB1降低突变细胞MMP7基因表达(P<0.0001),微血管密度未增加。
核心结论
- 数据为GOG-86P中CTNNB1突变子宫内膜癌对贝伐珠单抗应答提供了机制性解释。
- 作者假说过表达并分泌的MMP7可能消化VEGFR-1、释放VEGF-A并增加其可利用性,从而驱动可渗透血管形成,促进肿瘤进展、转移与免疫抑制。
- 该机制为子宫内膜癌所独有,作者主张开展进一步临床试验评估这一治疗相关生物标志物。
研究设计与样本
- 研究分析TCGA的RNA表达与CPTAC的蛋白表达以识别β-catenin过度活化的可能靶点。
- 在子宫内膜癌细胞中瞬时和稳定过表达β-catenin以验证计算机分析结果。
- 在突变细胞系中沉默CTNNB1以验证功能特异性。
- 将转导细胞植入异种移植模型研究微血管密度。
主要发现
- CTNNB1突变子宫内膜癌与β-catenin及MMP7蛋白丰度升高相关(P<0.001),与VEGF-A蛋白丰度升高不相关。
- 子宫内膜癌细胞过表达β-catenin不增加VEGF-A丰度,但增加MMP7表达与分泌(P<0.03)。
- 在CTNNB1突变细胞中沉默CTNNB1降低子宫内膜癌MMP7基因表达(P<0.0001)。
- 微血管密度未增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment options and associated biomarkers for advanced and recurrent disease are limited. Endometrial cancers (ECs) with CTNNB1 exon 3 mutations appear to have preferential response to bevacizumab, an anti-angiogenesis treatment, though the mechanism of action is unknown. We aim to identify mediators of bevacizumab-responsive endometrial cancers. METHODS: We analyzed RNA expression from TCGA and protein expression from CPTAC to identify likely targets for β-catenin overactivity. We then transiently and stably overexpressed β-catenin in EC cells to confirm the results suggested by our in silico analysis. We performed corroborative experiments by silencing CTNNB1 in mutated cell lines to demonstrate functional specificity. We implanted transduced cells into xenograft models to study microvessel density. RESULTS: CTNNB1-mutated ECs were associated with increased β-catenin and MMP7 protein abundance (P < 0.001), but not VEGF-A protein abundance. Overexpressing β-catenin in EC cells did not increase VEGF-A abundance but did increase expression and secretion of MMP7 (P < 0.03). Silencing CTNNB1 in CTNNB1-mutated cells decreased MMP7 gene expression in EC (P < 0.0001). Microvessel density was not increased. CONCLUSIONS: These data provide a mechanistic understanding for bevacizumab-response in CTNNB1-mutated ECs demonstrated in GOG-86P. We hypothesize that overexpressed and secreted MMP7 potentially digests VEGFR-1, releasing VEGF-A, and increasing its availability. These activities may drive the formation of permeable vessels, which contributes to tumor progression, metastasis, and immune suppression. This mechanism is unique to EC and advocates for further clinical trials evaluating this treatment-related biomarker.
引用
- Berger AA, Kawaler EA, Dao F, et al. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma. Gynecol Oncol. 2022. PMID: 36150916. doi:10.1016/j.ygyno.2022.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。